RDN:ESH
461 videos | 485 followers
European Society of Hypertension Position Paper Roundtable
What difference will recent updates in hypertension consensus documents and trials have to patients under you care?
Would you consider RDN as the 3rd pillar for hypertension control?
How do you see this helping support your local consensus statement?
The STEP trial showed a significant reduction in clinical events with similar levels of blood pressure reduction as RDN. What are the implications of RDN therapy?
Are you comfortable with the safety and efficacy profiles for RDN?
How do you plan to use recent data and consensus statement updates with your patients, to advance treatment in HTN program?
Dr. Jose Antonio Garcia Donaire on plans to use recent data and consensus statement updates with patients, to advance treatment in HTN program
HTN:RDN
How do consensus and trial updates support patient selection?
How are you going to share updates with your referring community?
What is the importance of shared decision-making process in hypertension control?
Highlighted Event
Renal Denervation: Moving from research to clinical practice
- 1H
Join this roundtable to hear Dr. Justin Davies, Prof Konstantinos Tsioufis, and Prof. Roland Schmieder discuss the latest ESH Position Paper on Renal Denervation. Updated proposed recommendations was deemed necessary, by the ESH, after the publication of a set of new pivotal sham-controlled randomized clinical trials (RCTs), which provided important information about the efficacy and safety of endovascular device-based renal denervation (RDN) for hypertension treatment, positioning RDN as a third pillar for hypertension treatment.
Add to calendar